Advances in endometrial cancer protein biomarkers for use in the clinic

Expert Review of Proteomics

Volumn 15, Issue 1, 2018, Pages 81-99

  Martinez Garcia, Elena ^a   Lopez Gil, Carlos ^a   Campoy, Irene ^a   Vallve, Julia ^a   Coll, Eva ^a   Cabrera, Silvia ^b   Ramon Y Cajal, Santiago ^b   Matias Guiu, Xavier ^c,d   Van Oostrum, Jan ^e   Reventos, Jaume ^d,f   Gil Moreno, Antonio ^a,b   Colas, Eva ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^f UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

Author keywords

Biomarker; biomarker pipeline; bodyfluid; diagnosis; endometrial cancer; liquid biopsy; mass spectrometry; proteomics; study design

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

CANCER DIAGNOSIS; CANCER RESEARCH; CLINICAL STUDY; ENDOMETRIUM CANCER; FEMALE; HOSPITAL; HUMAN; MASS SPECTROMETRY; NONHUMAN; PROTEIN ANALYSIS; REVIEW; VALIDATION STUDY;

EID: 85039855721     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1080/14789450.2018.1410061     Document Type: Review

References (67)

1. Siegel RL, Miller KD, Jemal A., Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.
2. Siegel R, Naishadham D, Jemal A., Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.
3. Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387:1094–1108.
4. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15:10–17.
5. Cancer Genome Atlas Research Network, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.
6. Brinton, L. A., Felix, A. S., McMeekin, D. S., et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013;129:277–284.
7. Van Hanegem, N., Breijer, M. C., Khan, K. S. Diagnostic evaluation of the endometrium in postmenopausal bleeding: an evidence-based approach. Maturitas. 2011;68:155–164.
8. Lacey JV, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009;63:39–44.
9. Colombo, N., Creutzberg, C., Amant, F., et al. ESMO-ESGO-ESTRO Consensus Conference on endometrial cancer: diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:16–41.
10. Timmermans A, Opmeer, B. C., Khan, K. S. Endometrial thickness measurement for detecting endometrial cancer in women with postmenopausal bleeding: a systematic review and meta-analysis. Obstet Gynecol. 2010;116:160–167.
11. SGO Clinical Practice Endometrial Cancer Working Group, et al. Endometrial cancer: a review and current management strategies: part I. Gynecol Oncol. 2014;134:385–392.
12. Clark, T. J., Mann, C. H., Shah, N. Accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer: a systematic quantitative review. BJOG Int J Obstet Gynaecol. 2002;109:313–321.
13. Bradley LD. Complications in hysteroscopy: prevention, treatment and legal risk. Curr Opin Obstet Gynecol. 2002;14:409–415.
14. Abdelazim IA, Aboelezz A, AbdulKareem AF. Pipelle endometrial sampling versus conventional dilatation & curettage in patients with abnormal uterine bleeding. J Turk Ger Gynecol Assoc. 2013;14:1–5.
15. Clark, T. J., Voit, D., Gupta, J. K. Accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA. 2002;288:1610–1621.
16. Borrebaeck CAK. Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer. Nat Rev Cancer. 2017;17:199–204.
17. Li D, Chan DW. Proteomic cancer biomarkers from discovery to approval: it’s worth the effort. Expert Rev Proteomics. 2014;11:135–136.
18. Ebhardt HA, Root A, Sander C, et al. Applications of targeted proteomics in systems biology and translational medicine. Proteomics. 2015;15:3193–3208.
19. Aebersold, R., Anderson, L., Caprioli, R. Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res. 2005;4:1104–1109.
20. Tainsky MA. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta. 2009;1796:176–193.
21. Yeramian, A., Moreno-Bueno, G., Dolcet, X. Endometrial carcinoma: molecular alterations involved in tumor development and progression. Oncogene. 2013;32:403–413.
22. Albrethsen J. The first decade of MALDI protein profiling: a lesson in translational biomarker research. J Proteomics. 2011;74:765–773.
23. Aebersold R, Goodlett DR. Mass spectrometry in proteomics. Chem Rev. 2001;101:269–295.
24. Ducret A, Van Oostveen I, Eng JK, et al. High throughput protein characterization by automated reverse-phase chromatography/electrospray tandem mass spectrometry. Protein Sci Publ Protein Soc. 1998;7:706–719.
25. Hebert, A. S., Richards, A. L., Bailey, D. J. The one hour yeast proteome. Mol Cell Proteomics MCP. 2014;13:339–347.
26. Bekker-Jensen, D. B., Kelstrup, C. D., Batth, T. S. An optimized shotgun strategy for the rapid generation of comprehensive human proteomes. Cell Syst. 2017;4:587–599.
27. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem. 2004;76:4193–4201.
28. Tabb, D. L., Vega-Montoto, L., Rudnick, P. A. Repeatability and reproducibility in proteomic identifications by liquid chromatography-tandem mass spectrometry. J Proteome Res. 2010;9:761–776.
29. Shao S, Guo T, Aebersold R. Mass spectrometry-based proteomic quest for diabetes biomarkers. Biochim Biophys Acta. 2015;1854:519–527.
30. Whiteaker, J. R., Lin, C., Kennedy, J. A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol. 2011;29:625–634.
31. Wang P, Whiteaker JR, Paulovich AG. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther. 2009;8:1083–1094.
32. Diamandis, EP. Cancer biomarkers: can we turn recent failures into success? JNCI J Natl Cancer Inst. 2010;102:1462–1467.
33. Füzéry AK, Levin J, Chan MM, et al. Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges. Clin Proteomics. 2013;10:13.
34. Pavlou, MP, Diamandis, EP, Blasutig IM. The long journey of cancer biomarkers from the bench to the clinic. Clin Chem. 2013;59:147–157.
35. Ioannidis JPA. Biomarker failures. Clin Chem. 2013;59:202–204.
36. Sivridis E, Giatromanolaki A. The pathogenesis of endometrial carcinomas at menopause: facts and figures. J Clin Pathol. 2011;64:553–560.
37. Rai P, Kota V, Sundaram CS, et al. Proteome of human endometrium: identification of differentially expressed proteins in proliferative and secretory phase endometrium. Proteomics Clin Appl. 2010;4:48–59.
38. Drabovich AP, Martínez-Morillo E, Diamandis EP. Toward an integrated pipeline for protein biomarker development. Biochim Biophys Acta. 2015;1854:677–686.
39. Anderson NL, Anderson NG. The human plasma proteome history, character, and diagnostic prospects. Mol Cell Proteomics. 2002;1:845–867.
40. Rifai, N, Gillette, MA, Carr, SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol. 2006;24,:971–983.
41. Colas, E., Perez, C., Cabrera, S. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int J Cancer J Int Cancer. 2011;129:2435–2444.
42. Esteller M, García A, Martínez-Palones JM, et al. Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart. Lab Investig J Tech Methods Pathol. 1997;76:109–116.
43. El Behery MM, Huda MH, Kamal EM, et al. Diagnostic accuracy of uterine fluid lactate dehydrogenase isoenzyme activity profile and vaginal ultrasound in detecting endometrial cancer in women with postmenopausal bleeding. Arch Gynecol Obstet. 2010;281:717–721.
44. Martinez, E., Lesur, A., Devis, L. Targeted proteomics identifies proteomic signatures in liquid-biopsies of the endometrium to diagnose endometrial cancer and assist in the prediction of the optimal surgical treatment. Clin Cancer Res Off J Am Assoc Cancer Res. 2017 Nov 1;23(21):6458–6467.
45. Fiegl, H., Gattringer, C., Widschwendter, A. Methylated DNA collected by tampons–a new tool to detect endometrial cancer. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. 2004;13:882–888.
46. He, S.-M., Xing, F., Sui, H. Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. Med Sci Monit Int Med J Exp Clin Res. 2011Nov;17(11):CR618–625.
47. Kinde, I., Bettegowda, C., Wang, Y. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med. 2013;5:167ra4.
48. Venable JD, Dong M-Q, Wohlschlegel J, et al. Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra. Nat Methods. 2004;1:39–45.
49. Collins, B. C., Gillet, L. C., Rosenberger, G. Quantifying protein interaction dynamics by SWATH mass spectrometry: application to the 14-3-3 system. Nat Methods. 2013;10:1246–1253.
50. Toprak, U. H., Gillet, L. C., Maiolica, A. Conserved peptide fragmentation as a benchmarking tool for mass spectrometers and a discriminating feature for targeted proteomics. Mol Cell Proteomics MCP. 2014;13:2056–2071.
51. Hou, G., Lou, X., Sun, Y. Biomarker discovery and verification of esophageal squamous cell carcinoma using integration of SWATH/MRM. J Proteome Res. 2015;14:3793–3803.
52. Ortea I, Rodríguez-Ariza A, Chicano-Gálvez E, et al. Discovery of potential protein biomarkers of lung adenocarcinoma in bronchoalveolar lavage fluid by SWATH MS data-independent acquisition and targeted data extraction. J Proteomics. 2016;138:106–114.
53. Luo, Y., Mok, T. S., Lin, X. SWATH-based proteomics identified carbonic anhydrase 2 as a potential diagnosis biomarker for nasopharyngeal carcinoma. Sci Rep. 2017;7:41191.
54. Yang, L., Wang, J., Li, J. Identification of serum biomarkers for gastric cancer diagnosis using a human proteome microarray. Mol Cell Proteomics MCP. 2016;15:614–623.
55. Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci USA. 2007;104:17494–17499.
56. Paulovich AG, Whiteaker JR, Hoofnagle AN, et al. The interface between biomarker discovery and clinical validation: the tar pit of the protein biomarker pipeline. Proteomics Clin Appl. 2008;2:1386–1402.
57. Method of the year. 2012. Nat Methods. 2013;10:1.
58. Picotti P, Aebersold R. Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions. Nat Methods. 2012;9:555–566.
59. Gallien S, Duriez E, Domon B. Selected reaction monitoring applied to proteomics. J Mass Spectrom JMS. 2011;46:298–312.
60. Peterson AC, Russell JD, Bailey DJ, et al. Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol Cell Proteomics MCP. 2012;11:1475–1488.
61. Lesur A, Domon B. Advances in high-resolution accurate mass spectrometry application to targeted proteomics. Proteomics. 2015;15:880–890.
62. Domon B, Gallien S. Recent advances in targeted proteomics for clinical applications. Proteomics Clin Appl. 2015;9:423–431.
63. Martinez-Garcia, E., Lesur, A., Devis, L. Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples. Oncotarget. 2016. DOI:10.18632/oncotarget.10632.
64. Knific, T., Osredkar, J., Smrkolj, Š. Novel algorithm including CA-125, HE4 and body mass index in the diagnosis of endometrial cancer. Gynecol Oncol. 2017;147:126–132.
65. Skates, S. J., Gillette, M. A., LaBaer, J. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res. 2013;12:5383–5394.
66. IARC Publications Website - World Cancer Report 2014. [cited 2017 Apr17].Available from: http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014.
67. World Health Organization. Cancer control: early detection WHO guide for effective programmes. Geneve: WHO; 2007.